A crossing in therapy for hepatitis C virus genotype 2 or 3: increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard duration.
Huang
Chung-Feng
CF
Dai
Chia-Yen
CY
Huang
Jee-Fu
JF
Chuang
Wan-Long
WL
Yu
Ming-Lung
ML